Mortality according to CD4 count at start of combination antiretroviral therapy among HIV positive patients followed for up to 15 years after start of treatment: collaborative cohort study
- May, Margaret T
- Vehreschild, Jorg-Janne
- Trickey, Adam
- Obel, Niels
- Reiss, Peter
- Bonnet, Fabrice
- Mary-Krause, Murielle
- Samji, Hasina
- Cavassini, Matthias
- Gill, Michael John
- Shepherd, Leah
- Crane, Heidi
- D 'arminio, Antonella
- Burkholder, Greer
- Johnson, Margaret
- Sobrino, Paz
- Domingo, Pere
- Zangerle, Robert
- Justice, Amy C
- Sterling, Timothy
- Miro, Jose
- Sterne, Jonathan A.C.
DOIAbstract
Writing committee: The Antiretroviral Therapy Cohort Collaboration (ART-CC)International audienceBackground. CD4 count at start of combination antiretroviral therapy (ART) is strongly associated with short-term survival, but its association with longer-term survival is less well characterised.Methods. We estimated mortality rates (MR) by time since start of ART (10 years respectively.Conclusions. After surviving five years of ART, the mortality of patients who started ART with low baseline CD4 count converged with mortality of patients with intermediate and high baseline CD4 counts
Add to ORKG